Skip to main content

Table 3 Activity of omadacycline and comparator agents against a range of bacterial pathogens from 25 teaching hospitals in China

From: Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

Antimicrobial agent by organism or organism group (no. tested) MIC50 (mg/L) MIC90 (mg/L) S (%) R (%) NS (%)
Staphylococcus aureus (197)
 Omadacycline 0.12 0.25 98.5 a 0.5 a  
 Tigecycline 0.12 0.25 99.5   0.5
 Tetracycline 16 64 36.0 58.9  
 Clindamycin 0.12 8 64.5 34.0  
 Daptomycin 0.5 1 99.0   1.0
 Gentamicin 0.5 64 59.9 33.5  
 Levofloxacin 4 8 48.2 50.8  
 Linezolid 1 2 99.5 0.5  
 Oxacillin 2 8 50.8 49.2  
 Trimethoprim-sulfamethoxazole 0.25 1 96.4 3.6  
 Vancomycin 1 1 100.0 0.0  
Enterococcus spp. (25)
 Omadacycline 0.03 0.12 100.0 b 0.0 b  
 Tigecycline 0.12 0.25 100.0   0.0
 Minocycline 16 16 40.0 52.0  
 Tetracycline 64 64 24.0 76.0  
 Daptomycin 1 2 100.0 0.0  
  Moxifloxacin 8 8 16.0 84.0  
 Linezolid 2 2 100.0 0.0  
 Vancomycin 1 2 96.0 4.0  
Streptococcus pneumoniae (59)
 Omadacycline 0.06 0.06 96.6 0.0  
 Tigecycline <0.03 0.03 94.9   5.1
 Tetracycline 32 64 6.8 89.8  
 Ceftriaxone 0.25 4 81.4 11.9  
 Erythromycin 2 2 22.0 76.3  
 Levofloxacin 1 1 98.3 1.7  
 Linezolid 1 1 100.0 0.0  
 Penicillin 0.12 4 89.8 1.7  
Enterobacterales (651)
 Omadacycline 2 8 81.7 c 8.6 c  
 Tigecycline d 0.5 2 91.6 d 1.1 d  
 Minocycline 4 32 34.6   56.2
 Tetracycline 64 64 33.9 61.6  
 Amikacin 4 16 85.7 8.6  
 Ciprofloxacin 2 64 57.8 35.6  
 Ceftazidime 64 64 42.1 56.2  
 Ceftriaxone 0.5 2 85.3 8.8  
 Imipenem 1 4 40.7 52.7  
 Piperacillin-tazobactam 4 128 70.5 24.1  
Escherichia coli (260)
 Omadacycline 1 4 92.3 4.6  
 Tigecycline d 0.25 1 94.6 d 0.4 d  
 Minocycline 8 21 0.0 99.6  
 Tetracycline 64 64 14.6 85.0  
 Aztreonam 8 32 46.2 49.6  
 Amikacin 4 8 80.0 7.7  
 Ciprofloxacin 4 4 29.2 63.5  
 Ceftazidime 2 64 59.2 32.7  
 Ceftriaxone 64 64 41.2 58.5  
 Imipenem 0.5 0.5 96.2 2.7  
 Piperacillin-tazobactam 4 128 81.9 13.5  
Klebsiella pneumoniae (271)
 Omadacycline 2 16 70.5 13.3  
 Tigecycline d 1 4 86.7 d 2.2 d  
 Minocycline 4 64 51.3 32.5  
 Tetracycline 8 64 46.5 46.9  
 Aztreonam 16 32 45.4 52.8  
 Amikacin 4 64 86.7 12.5  
 Ciprofloxacin 0.5 4 43.9 49.8  
 Ceftazidime 4 64 52.8 42.1  
 Ceftriaxone 64 64 38.7 59.8  
 Imipenem 0.5 32 81.9 14.4  
 Piperacillin-tazobactam 4 128 63.8 31.7  
Acinetobacter baumannii (198)
 Omadacycline 4 16    
 Tigecycline 2 8    
 Minocycline 8 16 45.5 28.3  
 Tetracycline 64 64 16.2 81.3  
 Amikacin 64 64 29.8 69.7  
 Ciprofloxacin 4 4 21.2 76.8  
 Cefepime 64 256 19.7 75.8  
 Imipenem 32 64 24.7 75.3  
 Piperacillin-tazobactam 128 128 23.2 75.3  
Pseudomonas aeruginosa (30)
 Omadacycline 32 32    
 Tigecycline e 8 16    
 Minocycline 8 32    
 Tetracycline e 32 64 0.0 100.0 e  
 Amikacin 4 8 93.3 6.7  
 Ciprofloxacin 0.25 4 73.3 23.3  
 Cefepime 1 64 73.3 20.0  
 Imipenem 1 16 80.0 20.0  
 Piperacillin-tazobactam 8 128 63.3 20.0  
  1. aUsing FDA identified breakpoints for ABSSSIs
  2. bUsing FDA identified breakpoints for Enterococcus faecalis
  3. cUsing FDA identified breakpoints for Klebsiella pneumoniae and Enterobacter cloacae
  4. dUsing EUCAST clinical breakpoints for tigecycline
  5. eTigecycline and tetracycline are inherent resistant against Pseudomonas aeruginosa ccording to CLSI document M100ED29E